“Shift toward Biologic and Targeted Therapies”
A notable trend in the global non-infectious uveitis market is the increasing shift toward biologic drugs and targeted therapies. This transition reflects a growing preference for treatments that offer more precision in addressing the underlying causes of uveitis, particularly those associated with autoimmune diseases. Unlike traditional corticosteroids, which can have significant side effects when used long-term, biologics such as TNF-alpha inhibitors and interleukin inhibitors provide more targeted action, focusing on specific immune pathways involved in inflammation. This approach not only enhances treatment efficacy but also minimizes adverse effects, making it a preferred option for many patients. The rising adoption of these therapies is improving overall treatment outcomes and changing the landscape of uveitis management, as healthcare providers increasingly opt for drugs that offer better control of the disease with fewer complications.
